[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea]

Nihon Yakurigaku Zasshi. 2009 May;133(5):281-91. doi: 10.1254/fpj.133.281.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Benzimidazoles / adverse effects
  • Benzimidazoles / pharmacology*
  • Benzimidazoles / therapeutic use*
  • Clinical Trials as Topic
  • Diarrhea / drug therapy*
  • Diarrhea / etiology
  • Dose-Response Relationship, Drug
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Irritable Bowel Syndrome / etiology
  • Randomized Controlled Trials as Topic
  • Serotonin 5-HT3 Receptor Antagonists
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / pharmacology*
  • Serotonin Antagonists / therapeutic use*
  • Stress, Psychological / complications

Substances

  • Benzimidazoles
  • Serotonin 5-HT3 Receptor Antagonists
  • Serotonin Antagonists
  • ramosetron